• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
AVH
Click for more information
5.42% $2.62

AVITA MEDICAL INC. - Charts / Financials

Market Cap $157.7M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Biotechnology

AVITA Medical, Inc. is a commercial-stage regenerative medicine company. The Company is a... AVITA Medical, Inc. is a commercial-stage regenerative medicine company. The Company is a provider of regenerative medicine addressing unmet medical needs in burn injuries, full-thickness skin defects, and in skin repigmentation, such as vitiligo. Its RECELL platform a single use, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators. RECELL is used for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. The platform technology of the RECELL System enables a thin split-thickness skin sample from the patient to be processed and prepared, producing an autologous cellular suspension called Spray-On Skin Cells. These Spray-On Skin Cells are prepared at the point of care in as little as 30 minutes, providing a new way to treat thermal burn wounds and full-thickness skin defects.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits
refresh Created with Sketch. REFRESH
Last update - 15.59pm 26/04/2024 (20 minute delay) ?
Day
Open $2.62   Day High $2.66   Day Low $2.58
Daily Volume 614020
Bids   Sellers
Number Price Volume   Number Price Volume
8 $2.61 13249   1 $2.66 3448

Directors & Senior Management

Mr. James M. Corbett President, Chief Executive Officer, Executive Director
Mr. David O Toole Chief Financial Officer
Mr. Terry Bromley Senior Vice President - Global Sales
Ms. Debbie Garner Senior Vice President - Global Marketing and Strategy
Mr. Andrew Quick Chief Technology Officer
Ms. Donna Shiroma General Counsel
Mr. Lou Panaccio Independent Non-Executive Chairman of the board
Mr. Robert E. Mcnamara Director
Mr. Cary G. Vance Director
Mr. Jeremy Curnock Cook Independent Non-Executive Director
Prof. Suzanne Crowe Independent Non-Executive Director

Data source: Refinitiv

(20min delay)
Last
$2.62 		Change
-0.150(5.42%) 		Mkt cap ! $157.7M
Open High Low Value Volume
$2.62 $2.66 $2.58 $1.612M 614.0K

Buyers (Bids)

No. Vol. Price($)
8 13249 $2.61
 

Sellers (Offers)

Price($) Vol. No.
$2.66 3448 1
View Market Depth
Last trade - 16.10pm 26/04/2024 (20 minute delay) ?
Last
$2.62 		  Change
-0.150 ( 6.19 %)
Open High Low Volume
$2.61 $2.65 $2.61 10832
Last updated 15.59pm 26/04/2024 ?

Top Stories

1970s on repeat, but there's a silver lining!

ABBA fans across Australia know that the 1970s were not only about nervous shuffles to the strains of Dancing Queen, across the linoleum floor at the local Blue Light Disco. Oil had only recently begun to rise, and so synthetic fabrics, like polyester, were very popular. So was central heating, using fuel oil. This is all ancient history now and it would not matter except for the fact that history is now rhyming so hard.
BHP confirms £31.1B takeover bid for Anglo American BHP HAS confirmed its offer to takeover fellow mining giant Anglo American plc, following press speculation of a potential deal.which had unsettled shareholder groups and financial firms in London, and provoked criticism from a South African government minister.
Raiden’s jump into lithium territory in WA’s Pilbara echoes earlier journey by Azure In its bid to define a noteworthy lithium deposit in WA’s Pilbara region, Raiden Resources is following in the footsteps of another explorer.
Are there gains to be made with the grocery giants? There is a growing storm of controversy around Coles (ASX:COL) and Woolworths (ASX:WOW) as they face intense scrutiny over price hikes and supplier pressures in a Senate inquiry. This raises an interesting question as to whether investors should cut ties with these corporate giants or wheth...
Recce Pharmaceuticals up 6% on new antibiotic production milestone Recce Pharmaceuticals (ASX:RCE) is trading up more than 6 per cent after producing a 5000-dose batch of its new antibiotic RECCE 327 (R327) under Good Manufacturing Practises (GMP) standards.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.